ARTICLE | Company News
KAHR, sanofi-aventis deal
April 25, 2011 7:00 AM UTC
In connection with its $2 million investment, sanofi-aventis received an option to the first right of negotiation to one of KAHR's two preclinical compounds. KAHR-101 is a fusion protein that links p...